Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 11 (Search time: 0.003 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2002
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
Branford, S.
;
Rudzki, Z.
;
Walsh, S.
;
Grigg, A.
;
Arthur, C.
;
Taylor, K.
;
Herrmann, R.
;
Lynch, K.
;
Hughes, T.
2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Druker, B.
;
Guilhot, F.
;
O'Brien, S.
;
Gathmann, I.
;
Kantarjian, H.
;
Gattermann, N.
;
Deininger, M.
;
Silver, R.
;
Goldman, J.
;
Stone, R.
;
Cervantes, F.
;
Hochhaus, A.
;
Powell, B.
;
Gabrilove, J.
;
Rousselot, P.
;
Reiffers, J.
;
Cornelissen, J.
;
Hughes, T.
;
Agis, H.
;
Fischer, T.
;
et al.
2013
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Branford, S.
;
Yeung, D.
;
Ross, D.
;
Prime, J.
;
Field, C.
;
Altamura, H.
;
Yeoman, A.
;
Georgievski, J.
;
Jamison, B.
;
Phillis, S.
;
Sullivan, B.
;
Briggs, N.
;
Hertzberg, M.
;
Seymour, J.
;
Reynolds, J.
;
Hughes, T.
2008
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
le Coutre, P.
;
Ottmann, O.
;
Giles, F.
;
Kim, D.
;
Cortes, J.
;
Gattermann, N.
;
Apperley, J.
;
Larson, R.
;
Abruzzese, E.
;
O'Brien, S.
;
Kuliczkowski, K.
;
Hochhaus, A.
;
Mahon, F.
;
Saglio, G.
;
Gobbi, M.
;
Kwong, Y.
;
Baccarani, M.
;
Hughes, T.
;
Martinelli, G.
;
Radich, J.
;
et al.
2000
A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia
Branford, S.
;
Rudzi, Z.
;
Hughes, T.
2003
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
Hughes, T.
;
Kaeda, J.
;
Branford, S.
;
Rudzki, Z.
;
Hochhaus, A.
;
Hensley, M.
;
Gathmann, I.
;
Bolton, A.
;
van Hoomissen, I.
;
Goldman, J.
;
Radich, J.
2010
Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia
Saglio, G.
;
Kim, D.
;
Issaragrisil, S.
;
le Coutre, P.
;
Etienne, G.
;
Lobo, C.
;
Pasquini, R.
;
Clark, R.
;
Hochhaus, A.
;
Hughes, T.
;
Gallagher, N.
;
Hoenekopp, A.
;
Haque, A.
;
Dong, M.
;
Larson, R.
;
Kantarjian, H.
2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Muller, M.
;
Cortes, J.
;
Kim, D.
;
Druker, B.
;
Erben, P.
;
Pasquini, R.
;
Branford, S.
;
Hughes, T.
;
Radich, J.
;
Ploughman, L.
;
Mukhopadhyay, J.
;
Hochhaus, A.
2012
Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response
White, D.
;
Hughes, T.
2007
Imatinib increases the intracellular concentration of nilotinib which may explain the observed synergy between these drugs
White, D.
;
Saunders, V.
;
Quinn, S.
;
Manley, P.
;
Hughes, T.
Discover
Author
6
Branford, S.
5
Hochhaus, A.
3
Kim, D.
3
Radich, J.
3
Rudzki, Z.
2
Arthur, C.
2
Cortes, J.
2
Druker, B.
2
et al.
2
Gathmann, I.
.
next >
Subject
10
Pyrimidines
9
Female
9
Piperazines
8
Benzamides
8
Imatinib Mesylate
8
Middle Aged
7
Adult
7
Aged
7
Leukemia, Myelogenous, Chronic, B...
6
Antineoplastic Agents
.
next >
Date issued
3
2010 - 2013
8
2000 - 2009